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ABSTRACT
Background In untreated acromegaly patients, decreased cognitive functioning is reported to be associated
with the degree of growth hormone (GH) and IGF-1 excess. Whether previous GH excess or current medical
treatment for acromegaly specifically affects cognition remains unclear. The aim of this study was to compare
cognitive functioning of patients who are treated for acromegaly with patients with non-functioning pituitary ade-
nomas (NFA). In addition, we assessed the influence of prolonged medical treatment after initial transsphenoidal
surgery on cognition.
Design In this cross-sectional study, 74 patients participated, who were treated for acromegaly (n = 50; median
[interquartile range] age: 53 [45–65] years) or NFA (n = 24; age: 63 [59–70] years). The NFA patients were
selected for a high likelihood of normal GH secretion based on an IGF-1 z-score within the normal range (> )2)
and zero or one axis substituted. Of the acromegaly patients, 28 had achieved remission, while 22 were bio-
chemically controlled with long-acting somatostatin analogues and ⁄or pegvisomant. Memory and executive
functioning were assessed by the 15 Words Test and the Ruff Figural Fluency Test, and reported as z-scores.
Results The total patient group scored significantly poorer than the reference population on memory and execu-
tive functioning (P < 0Æ001). However, cognitive test performance was not significantly different between
acromegaly patients with a persistent disease, acromegaly patients in remission and NFA patients.
Conclusion The total patient group scored worse compared with reference populations. We found no associa-
tion between previous GH excess and cognition. In addition, current medical treatment for GH excess in
acromegaly was not related to memory and executive functioning.
Keywords Acromegaly, cognition, growth hormone, IGF-1, pegvisomant therapy, somatostatin analog therapy.
Eur J Clin Invest 2012; 42 (12): 1317–1324
Introduction
Changes in cognitive functioning can be expected as a conse-
quence of growth hormone (GH) excess, or GH deficiency. The
reason for this assumption is a wide distribution of binding
sites for Insulin-like growth factor-1 (IGF-1) in the brain in
particular in the medial temporal lobe (the hippocampus) and
in the prefrontal cortex [1]. Indeed, studies on the effects of GH
and IGF-1 on cognition performed in GH deficient patients
demonstrated a link between GH and cognitive performance,
where poor performance was ameliorated with GH treatment
[2–4].
In acromegaly, which is characterized by excess GH produc-
tion, cognitive functioning is also reported to be impaired. In a
recent study, Leon-Carrion et al. [5] compared patients with
active acromegaly with healthy participants. They found a
moderate to severe memory impairment in patients and
postulated that high levels of GH and IGF-I in acromegaly
patients could be the basis for these findings. However,
comparisons with untreated acromegaly patients are less
informative because nonspecific psychological factors associ-
ated with chronic illness will undoubtedly influence the results
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[6]. In another study, Sievers and colleagues compared
acromegaly patients (of which 60% was either cured or bio-
chemically controlled) with healthy individuals [7]. They found
that cognitive dysfunction, particularly attentional deficits,
were common in acromegaly. Although this finding is of
importance, again comparisons were made with healthy
controls. More informative would be a comparison with
patients who have non-functioning pituitary adenomas (NFA).
These patients share many disease characteristics but do not
have the GH excess. This type of study was performed by
Tiemensma et al. [8], who concluded that there was normal
cognitive functioning after long-term cure for acromegaly. The
relation of previous GH excess with impaired cognitive
functioning remains however controversial due to these
inconsistent study results.
In acromegaly, GH and IGF1 may be discordant on medica-
tion during persistent disease. Biermasz et al. [9] demonstrated
that octreotide did not lead to orderly GH secretion in acro-
megaly in spite of normalization of IGF-1. Neggers et al. [10]
postulated that long-acting somatostatin analogues normalize
serum IGF1 levels in certain patients in the presence of elevated
GH actions in extrahepatic tissues. This phenomenon was
called extrahepatic acromegaly. This change in diurnal GH pro-
file, while IGF-1 is normalized, potentially also influences cog-
nitive functioning. Until now no research is available on the
effects of medical treatment in acromegaly on cognition.
With these considerations in mind, we studied acromegaly
patients with persistent disease (i.e. on GH suppressive media-
tion) and compared them with acromegaly patients who were
in remission. In addition, comparisons were made to NFA
patients, to investigate the effects of previous GH excess.
Methods andmaterials
Patients
In this cross-sectional study, patients were recruited for partici-
pation at the endocrine outpatient clinic of the University Medi-
cal Center Groningen (UMCG), a tertiary referral centre for
pituitary surgery in the Netherlands. Inclusion criteria were as
follows: age ‡ 18 years, treatment for acromegaly or NFA and
regular follow-up in our endocrine outpatient clinic (i.e. at least
once a year). Additional in-and exclusion criteria, details of the
study protocol and definitions of hormone deficiencies are
described elsewhere [11]. Briefly, NFA and acromegaly patients
were tested between September 2008 and November 2011. The
diagnosis of NFA was based on two criteria: presence of a pitui-
tary macroadenoma (> 1 cm) on magnetic resonance imaging
and absence of overproduction of any of the pituitary
hormones. The selection of the NFA patients was based on the
absence of GH substitution, IGF-1 z-scores within the
age-adjusted normal range (> )2) and zero or one axis being
substituted. Pituitary deficiencies were defined according to
generally accepted guidelines. The initial diagnosis of acro-
megaly was based on the characteristic clinical signs and symp-
toms and confirmed by insufficient suppression of GH during
an oral glucose tolerance test (oGTT), elevated age-adjusted
IGF-1 concentrations and the presence of a pituitary adenoma
on radiological imaging. Of the acromegaly patients who were
included in this study, 28 were in remission [i.e. they had IGF-1
levels in the normal range, and a normal suppression of GH on
oGTT (< 1Æ0 lg ⁄L)], while 22 had persistent disease and were
still treated with long-acting somatostatin analogues and ⁄or
pegvisomant. The consecutive approach to our acromegaly
study patients was considered to be representative for the
patient group, as published previously for NFA patients [12].
IGF-1 assay
Plasma IGF-1 was measured by radioimmunoassay after acid–
ethanol extraction (Nichols Institute of Diagnostics, San-Juan
Capistrano, CA, USA) [13]. IGF-1 was measured on the day of
testing. Data are reported as IGF-1 z-scores.
Cognitive tests
Aspects of verbal memory were assessed with the 15 Words
Test (15 WT) which is a Dutch equivalent of the Rey Auditory
Verbal Learning Test [14]. In this test, 15 words were presented
five times. After each trial, patients were asked to name imme-
diately the words they remembered. This allowed the calcula-
tion of three different scores describing immediate memory:
1 The short-term memory score is based on the number of words
patients were able to name after the first presentation of the
word list.
2 The total memory score represents the total number of words
patients remembered over the five trials.
3 The learning score describes the difference between the
number of words remembered in the third trial in compari-
son with the first trial.
Besides immediate memory, delayed memorywas measured.
4 The delayed memory score is based on the number of words
patients could recall after a period of about 30 min.
Executive functioning was assessed using the Ruff Figural
Fluency Test (RFFT) [15]. In this test, patients were presented
with sheets of paper on which 35 squares were printed, each
with a fixed pattern of five dots. The test consisted of five parts,
which differed with regard to the designs. While the configura-
tions of dots are the same in the first three parts of the test, two
types of distractions are added in two of these parts. In the last
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two parts, the configurations of the dots are different and with-
out distractions. The participant was asked to produce as many
different designs as possible by connecting two or more dots in
each square with straight lines. The time for each part was
restricted to 1 min so that the total test time was 5 min.
Responses were scored with regard to the total number of
unique designs generated over the five parts. The perseverative
errors score represents the total number of repetitions of the
same design drawn. The interrater variability (two independent
raters) was determined by Pearson’s r and was 0Æ99 for both
total unique designs and perseverative errors. The error ratio is
the total number of perseverative errors divided by the total
number of unique designs.
Questionnaires and protocol
A common questionnaire on demographic and health-related
data was used with special attention for educational level,
social status, full-time ⁄part-time employment, social security
benefit, comorbidity, use of medicine, cardiovascular risk
factors, traumatic brain injury and dementia. Education level
was determined using a Dutch education system, comparable
to the ISCED [16]. This scale ranges from 1 (elementary school
not finished) to 7 (university level).
The Hospital Anxiety and Depression Scale (HADS) was
used to measure symptoms of anxiety and depression and
consists of 14 items [17]. Each item is scored as a number, with
a maximum score for each subscale (anxiety or depression) of
21. Higher scores indicate more severe anxiety or depression.
In fixed order, the test protocol was as follows: (i) the 15 WT:
direct recall, (ii) the RFFT, (iii) a common questionnaire to
assess baseline information, (iv) physical examination: length,
weight, blood pressure, waist circumference, hip circumference
and compliance to the test situation, (v) the HADS and finally
(vi) the 15 WT: delayed recall.
The assessment took approximately 40 min and was
performed directly after or just before patients’ visit to the
outpatient clinic. All testing and scoring of tests were
performed by trained personnel.
Reference data: healthy control subjects
The performances of patients were compared with Dutch con-
trols. Normative data for the HADS were derived from Spin-
hoven et al. [17]. In this study, general population mean and
standard deviations scores were used from 18 to 65 years and
> 65 years to calculate z-scores. Reference data for the 15 WT
were derived from control subjects of the Maastricht Aging
Study (n = 1780, aged 24–81 years) [14]. Regressions models
given by the authors were used to determine accurate z-scores.
The final test scores were controlled for age, sex and education.
Reference data for the RFFT were derived from a sample
(n = 10 289, half decades from 20 to 85 years) of the LifeLines
Cohort Study [18]. Using the mean and standard deviation
scores from this cohort, we standardized our patient scores by
converting it into z-scores.
Statistical analyses
The analyses were all carried out using the Predictive Analytics
software (PASW; SPSS, Inc., Armonk, NY, USA) statistics 18
package. Demographic data are presented as median and inter-
quartile range (IQR), frequencies or percentages. Normality of
data was analysed by QQ-plots. Not all data were distributed
normally; therefore, a nonparametric method was used to test
for differences between the groups on the cognitive measures.
Categorical variables were analysed using chi-squared tests (v2
test). Continuous variables were analysed by the Kruskal–Wal-
lis ANOVA. Cognitive performance data were presented as med-
ian and IQR. A nonparametric 95% confidence interval (CI) was
calculated according to the method of Campbell and Gardner
[19]. Furthermore, an impaired performance was defined as a
score £ 1Æ3 SD below the normative mean. Only 10% of the
overall normal population would be expected to score in this
range [20]. We compared three groups: acromegaly patients
with persistent disease, acromegaly patients in remission and
NFA patients. The two-tailed alpha level of < 0Æ05 was consid-
ered statistically significant. In case of statistical differences
between the groups on demographic or cognitive data, a Bon-
ferroni correction was performed to protect against Type I error
when performing multiple comparisons. In case of statistical
differences between the groups on demographic or cognitive
data, Duncan’s method was used as a post hoc test [21].
Reporting of the study conforms to STROBE statement along




Seventy-four patients participated in the present study (35 men,
39 women, aged 57 ± 12 years, range 22–81 years). Fifty
patients with acromegaly and 24 patients with NFA partici-
pated. The acromegaly patient group consisted of 22 patients
with a persistent disease and 28 patients who were in remis-
sion. Patients’ characteristics are given in Table 1. The acro-
megaly patient groups were significantly younger at surgery,
radiotherapy and time of testing compared with the NFA
patient group. Acromegaly patients with persistent disease
activity received significantly more often radiotherapy
compared with acromegaly patients who were in remission and
NFA patients. Furthermore, time since radiotherapy was longer
in acromegaly patients who were in remission compared with
acromegaly patients with persistent disease activity and NFA
patients. The IGF-1 z-scores were comparable between both
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Table 1 Clinical characteristics of acromegaly patients with persistent disease, acromegaly patients in remission and NFA patients
Acromegaly
NFA P-valuePersistent disease Patients in remission
N 22 28 24
Basic characteristics
Age (years), median [IQR] 54 [44; 62] 53 [45; 67] 63 [59; 70] 0Æ008
Sex (males ⁄ females) 11 ⁄ 11 12 ⁄ 16 12 ⁄ 12 0Æ837
Educational level (1 ⁄ 2 ⁄ 3 ⁄ 4 ⁄ 5 ⁄ 6 ⁄ 7) 0 ⁄ 2 ⁄ 0 ⁄ 4 ⁄ 7 ⁄ 7 ⁄ 2 0 ⁄ 2 ⁄ 0 ⁄ 6 ⁄ 12 ⁄ 8 ⁄ 0 0 ⁄ 1 ⁄ 0 ⁄ 5 ⁄ 10 ⁄ 8 ⁄ 0 0Æ674
Surgery
Age at surgery (years)
Median [IQR] 47 [38;56] 43 [36;55] 58 [51;64] 0Æ002
Average time since surgery (years)
Median [IQR] 5 [3; 7] 8 [4; 14] 5 [3;9] 0Æ203
< 1–5 years [number (%)] 50 36 50 0Æ458
5–10 years 36 25 37
> 10 years 14 39 13
Patients with 2nd surgery (%) 18 4 0 0.034
Use of GH suppressive medication
SA (N) (%) 9 (41%) NA NA
Peg (N) (%) 6 (27%) NA NA
SA and Peg (N) (%) 7 (32%) NA NA
Radiotherapy (RT)
RT after surgery (%) 64 21 17 0Æ001
Age at RT (years)
Median [IQR] 37 [32; 47] 47 [38; 57] 62 [49; 75] 0.046
Average time since RT (years)
Median [IQR] 4 [2; 7] 16 [11; 24] 4 [2; 4] 0.004
Hormonal substitution
No. of hormone replacements
(0 ⁄ 1 ⁄ 2 ⁄ 3 ⁄ 4 ⁄ 5)
12 ⁄ 5 ⁄ 3 ⁄ 1 ⁄ 1 ⁄ 0 19 ⁄ 6 ⁄ 2 ⁄ 0 ⁄ 1 ⁄ 0 10 ⁄ 14 ⁄ 0 ⁄ 0 ⁄ 0 ⁄ 0 0Æ070
Glucocorticoid (%) 32 14 17 0Æ269
Thyroid hormone (%) 27 14 13 0Æ356
GH (%) 0 7 0 0Æ379
Sex hormone (%) 18 11 29 0Æ237
Desmopressin (%) 5 4 0 0Æ579
IGF-1 z-score
Median [IQR] 0Æ42 [)0Æ43; 0Æ60] 0Æ69 [)0Æ27; 1Æ17] )1Æ12 [)1Æ56; )0Æ52] < 0.001
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acromegaly groups and significantly higher compared with the
NFA patient group, despite highly similar hormonal replace-
ments. Both acromegaly patient groups had significantly higher
anxiety z-scores (indicating more anxiety) in comparison with
the NFA patient group, although there was no indication for
clinical anxiety (z-scores within the normal range).
Cognitive tests
Cognitive performance data of the three groups are given in
Table 2. The 95% CIs fall below zero for all memory scores and
for the unique designs of the executive functioning test. For the
same variables, a higher proportion of patients scored in the
impaired range (all P < 0Æ001).
Z-scores for cognitive functioning in acromegaly patients
with persistent disease, acromegaly patients in remission and
matched NFA patients are given in Table 3. No significant
differences were found in median (IQR) cognitive z-scores
between the three groups.
Discussion
In the present study, we found no association between previous
GH excess and cognition. In addition, current medical treat-
ment for GH excess was not related to impairments in memory
and executive functioning. Although no differences were found
between patient groups, most test results differed significantly
from the reference populations, indicating a poor cognitive test
performance in both patients with acromegaly and NFA.
Only a few studies have addressed cognition in acromegaly.
Sievers et al. studied 55 patients with biochemically confirmed
Table 1 (Continued)
Acromegaly
NFA P-valuePersistent disease Patients in remission
HADS z-score
Anxiety 0Æ03 ()0Æ31; 0Æ54) 0Æ25 ()0Æ03; 0Æ81) )0Æ53 ()1Æ03; 0Æ40) 0.038
Depression )1Æ14 ()0Æ73; 0Æ56) )0Æ14 ()0Æ93; 0Æ94) )0Æ44 ()1Æ00; 1Æ04) 0.372
SA, somatostatin analogues, Peg, pegvisomant; GH, growth hormone; HADS, Hospital Anxiety and Depression Scale; IQR, interquartile range; NFA, non-
functioning pituitary adenomas.
Table 2 Cognitive performance of the total patient group
Median [IQR] 95% CI of the median




Short-term memory )0Æ36 [)1Æ29; 0Æ45] )0Æ61; )0Æ07 18 < 0Æ001
Total memory )0Æ80 [)1Æ60; 0Æ33] )1Æ00; )0Æ40 24 < 0Æ001
Learning score )0Æ51 [)1Æ28; 0Æ53] )0Æ74; )0Æ03 18 < 0Æ001
Delayed memory )0Æ80 [)1Æ73; 0Æ03] )1Æ20; )0Æ30 27 < 0Æ001
Executive functioning
Ruff Figural Fluency Test
Unique designs )0Æ52 [)1Æ51; 0Æ21] )0Æ94; )0Æ10 22 < 0Æ001
Perseverative errors 1Æ02 [0Æ04; 1Æ27] 0Æ76; 1Æ17 5 0Æ778
Error ratio 0Æ73 [0Æ17; 1Æ14] 0Æ61; 0Æ93 6 0Æ260
CI, confidence interval; IQR, interquartile range.
*P-values by chi-squared test comparing the number of patients who score in the impaired range to the number of patients who scored in the unimpaired
range.
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acromegaly and compared their data with 87 control subjects.
These patients were tested for attention, memory and executive
functioning. They found that 33% of the patients had an
impaired score (< 16th percentile) in the domain of attention,
24% in the domain of memory and up to 17% in the executive
functioning domain. However, no associations between the
patient’s performance and their status of biochemical control,
the current therapeutic regime or the estimated total time of
hormone excess, were found [7]. With ourmore stringent cut-off
values (£ 10th percentile), we also found a high proportion of
patients (72%) scoring in the impaired range on at least one out-
come variable independent of their status of biochemical control
and the current therapeutic regimen. In a study by Leon-
Carrion, moderate to severememory impairment was found in
acromegaly patients compared with healthy controls with
decreased neural activity in specific brain areas on quantitative
electroencephalogram [5]. A different approach to demonstrate
altered cognitive function was applied by Tanriverdi et al. [23].
In electrophysiological studies, they used the P300 amplitude,
which is related to updating of workingmemory (decision
making andmemory processing), and found that themean
amplitude at all electrode sites was significantly lower in 18
patients with acromegaly when comparedwith 16 healthy
controls and GHdeficient patients. However, the acromegaly
patients were enroled into the study before anymedical and
surgical intervention. Further, as the authors already acknowl-
edged themselves, the skull thickness may have interfered in the
measurements of the P300 amplitudes in acromegaly patients.
We decided to compare patients with biochemical control of
acromegaly to patients with a pituitary disease but without pre-
vious hormone excess. In accordance with the present findings,
Tiemensma et al. found that cognitive function in patients
cured from acromegaly did not differ from patients treated for
NFA. Intriguingly and in contrast to a bulk of evidence indicat-
ing that any disease (treatment) with its long-term effects
results in impairment of cognitive functioning, they found no
differences with matched controls [8].
In our study, all but one of the participating patients had
normal IGF-1 z-scores. In spite of this metabolic control, acro-
megaly patients with persistent disease who are on medication
are reported to have a disorderly GH secretion with repressed
secretory burst-mass and non-pulsatile secretion on octreotide
[9]. Another form of discordance is also described between GH
and IGF-1 in patients with acromegaly. Neggers et al. [10]
postulate that long-acting somatostatin analogues normalize
serum IGF1 levels in certain patients in the presence of elevated
GH actions in extrahepatic tissues. For these reasons, it is very
interesting to study the effects of medication in patients with
persistent disease and compare them with acromegaly patients
in remission. Previously, we demonstrated that quality of life is
impaired in association with the need for prolonged postopera-
tive therapy by somatostatin analogues in patients with
acromegaly [24]. With regard to cognition, Sonino found no
significant improvements in cognition after treatment with
octreotide [25] while others found improved cognitive
functions [26]. However, both studies assessed self-reported




Persistent disease Patients in remission
N = 22 N = 28 N = 24
Memory performance
15 Words Test
Short-term memory )0Æ74 [)1Æ69; 0Æ18] )0Æ28 [)0Æ89; 0Æ28] )0Æ28 [)1Æ17; 0Æ61] 0Æ274
Total memory )0Æ85 [)1Æ63; 0Æ23] )0Æ90 [)1Æ53; )0Æ10] )0Æ55 [)1Æ75; 0Æ60] 0Æ557
Learning score )0Æ03 [)0Æ65; 1Æ14] )0Æ63 [)1Æ60; 0Æ36] )0Æ67 [)1Æ12; 0Æ48] 0Æ088
Delayed memory )0Æ55 [)1Æ83; 0Æ28] )0Æ90 [)1Æ93; )0Æ10] 0Æ65 [)1Æ55; 0Æ08] 0Æ714
Executive functioning
Ruff Figural Fluency Test
Unique designs )0Æ83 [)1Æ51; 0Æ00] )0Æ29 [)1Æ42; 0Æ74] )0Æ62 [)1Æ61; 0Æ15] 0Æ538
Perseverative errors 1Æ05 [)0Æ32; 1Æ35] 1Æ04 [0Æ04; 1Æ31] 0Æ92 [0Æ26; 1Æ26] 0Æ926
Error ratio 0Æ56 [)0Æ90; 1Æ22] 0Æ80 [0Æ28; 1Æ13] 0Æ67 [0Æ22; 1Æ12] 0Æ691
Cognitive performance data are given as z-scores median [interquartile range].
NFA, non-functioning pituitary adenomas.
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cognition which is known to be often unrelated to objective
measures of cognition [27–29]. Further, within person
comparisons were made during active disease and controlled
disease, indicating that the effects may not per se be related to
GH and IGF-1 concentrations. We found no differences
between patients with persistent disease and patients who were
in remission in spite of far more extensive treatment in
persistent disease. This finding suggests that disease control by
normalization of IGF-1 alone might be sufficient for improve-
ments in cognitive functioning. This interpretation however
remains to be confirmed because our study is cross-sectional in
design and therefore limited to infer causality. Additional
studies should take GH secretory profiles in these patients into
account.
Some limitations need to be addressed. First, we did not use
an extensive battery of cognitive tests as is common in many
studies on cognitive functioning. We specifically chose for this
design to avoid multiple comparisons and thereby potentially
inducing type 1 errors. It allowed us also to test a larger group
than generally reported in the literature, thereby enhancing our
statistical power. However, for future studies an extensive
neuropsychological test battery is recommended, where
multiple cognitive domains are evaluated. Secondly, baseline
and treatment characteristics were at some points different
between groups. Although this is an inherent weakness of all
observational studies, potential effects have to be taken into
account. Previously, we found no negative effects of radio-
therapy on quality of life and cognition [11–13]. In regression
analysis, we also found no effects of radiotherapy (data not
shown).
In conclusion, we found no effects of previous GH excess on
cognition. Additionally, acromegaly patients on GH
suppressive medication with normal IGF-1 z-scores performed
similarly to acromegaly patients who were in remission and
NFA patients despite potential differences in diurnal GH con-
centrations. Based on these findings, the endocrinologist can
inform acromegaly patients that memory and executive func-
tioning are not expected to change as a consequence of the GH
excess in history or the GH suppressive medication. However,
patient groups had poorer cognitive performance corrected for
age, and educational level than the reference population, indi-
cating that other disease related factors may potentially be
important for cognition. Therefore, more research is needed in
the field of cognition in patients with hormonal deficits.
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